<code id='53C0B2C9DC'></code><style id='53C0B2C9DC'></style>
    • <acronym id='53C0B2C9DC'></acronym>
      <center id='53C0B2C9DC'><center id='53C0B2C9DC'><tfoot id='53C0B2C9DC'></tfoot></center><abbr id='53C0B2C9DC'><dir id='53C0B2C9DC'><tfoot id='53C0B2C9DC'></tfoot><noframes id='53C0B2C9DC'>

    • <optgroup id='53C0B2C9DC'><strike id='53C0B2C9DC'><sup id='53C0B2C9DC'></sup></strike><code id='53C0B2C9DC'></code></optgroup>
        1. <b id='53C0B2C9DC'><label id='53C0B2C9DC'><select id='53C0B2C9DC'><dt id='53C0B2C9DC'><span id='53C0B2C9DC'></span></dt></select></label></b><u id='53C0B2C9DC'></u>
          <i id='53C0B2C9DC'><strike id='53C0B2C9DC'><tt id='53C0B2C9DC'><pre id='53C0B2C9DC'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:knowledge    Page View:7958
          ASH19 CAR-T
          Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

          The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

          That sounds staggering to many patients — but it’s far less than analysts expected.

          advertisement

          The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In